Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
712 IMPORT-201 (IMP-MEL): a phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist (PORT-2) and pembrolizumab for advanced melanoma and non-small cell lung cancer (NSCLC)
Compose a Response to This Article
Other responses
No responses have been published for this article.
